A Rapid Blood Test for Early Detection of Prion Diseases

At a Glance

Researchers at Colorado State University have developed methods for detecting prions directly in blood samples with high sensitivity and specificity. The technology uses an advanced RT-QuIC assay to identify extremely small amounts of disease-associated prion material that traditional diagnostic methods cannot detect. The platform has demonstrated greater than 90% sensitivity with 100% specificity in blood samples from prion-infected deer and hamsters. This approach could support earlier diagnosis, disease surveillance, and improved blood safety monitoring for both human and animal prion diseases.

Background

Prion diseases, including chronic wasting disease (CWD) and variant Creutzfeldt-Jakob disease (vCJD), are fatal neurodegenerative disorders that can spread before symptoms appear. Existing diagnostic methods typically require nervous or lymphoid tissue and are not sensitive enough to reliably detect the very low levels of prions found in blood during early infection. Concerns surrounding asymptomatic carriers and potential blood-borne transmission have increased the need for accurate presymptomatic testing technologies. A sensitive blood-based assay could significantly improve disease monitoring, containment, and public health response efforts.

Overview

This technology improves conventional prion detection methods by adapting and optimizing real-time quaking-induced conversion (RT-QuIC) for use with whole blood samples. The assay amplifies trace amounts of prion-related amyloid material present in blood, allowing researchers to detect infections that would otherwise remain undetectable using standard approaches such as Western blotting or immunohistochemistry. The method enables rapid, reproducible screening while maintaining high analytical performance across multiple animal models and exposure routes.

In published studies, the assay successfully detected blood-borne prions in white-tailed deer, muntjac deer, and Syrian hamsters throughout disease progression, including within minutes of exposure and long before clinical symptoms developed. The platform achieved greater than 90% sensitivity while maintaining 100% specificity, demonstrating reliable detection of very low concentrations of circulating prions. The ability to detect prions directly in blood represents a major advancement for surveillance, diagnostic development, and understanding of how prion diseases spread through the body.

Benefits

Detects prions directly from whole blood samples
Greater than 90% sensitivity with 100% specificity demonstrated in animal studies
Capable of detecting prions during asymptomatic and early-stage infection
More sensitive than traditional tissue-based assays for low-level prion detection
Rapid and reproducible testing workflow
Supports both human and animal disease surveillance efforts
Provides insight into blood-borne transmission and disease progression
Applicable across multiple prion diseases and exposure routes